Author

Keruo Zhou

Observed name: Zhou, Keruo

Institution: Fosun Pharma (China)

Observed institutions: China Pharmaceutical University, Fosun Pharma (China), Shanghai Centennial Scientific (China)

ORCID: 0009-0003-4523-9031

Observed ORCID: 0009-0003-4523-9031

OpenAlex ID: A5032864526

Clinical outcomes of community pharmacy services: A systematic review and meta-analysis

2019 · Cancan Yuan, Yiwen Ding, et al. · Health & Social Care in the Community · 72

Cost-effectiveness analysis of budesonide/formoterol SMART therapy versus salmeterol/fluticasone plus as-needed SABA among patients ≥12 years with moderate asthma from the Chinese societal perspective

2024 · Keruo Zhou, Min Zhang, et al. · Journal of Medical Economics · 6

Co10 Assessing the Feasibility of Indirect Comparison of Luvometinib Versus Selumetinib in the Treatment for Pediatric Patients With Neurofibromatosis Type 1 in China

2026 · Lili Cheng, Zigang Li, et al. · Value in Health Regional Issues

Co74 Matching-adjusted Indirect Comparison of Luvometinib Versus Selumetinib in the Treatment for Pediatric Patients With Neurofibromatosis Type 1 in China

2026 · Chang Luo, Lili Cheng, et al. · Value in Health

Works count: 5

Citation count: 78

H-index: 2

I10-index: 1